9-Me-BC (9-Methyl-β-Carboline) 15MG

9-Me-BC (9-Methyl-β-Carboline) 15MG

9-Me-BC (9-Methyl-β-Carboline) 15MG

9-Me-BC (9-Methyl-β-Carboline) 15MG

9-Me-BC (9-Methyl-β-Carboline / 9-methylnorharmane) is an N9-methylated β-carboline and monoamine oxidase (MAO) inhibitor reference compound for dopaminergic-pathway and β-carboline structure-activity research. In enzyme assays, 9-Me-BC inhibits MAO-A (IC50 1 µM) at lower concentrations than MAO-B (IC50 15.5 µM), slowing the oxidative deamination of monoamines such as dopamine. CAS 2521-07-5.

$64.00

In stock

$64.00
Order now · ships tomorrow
Cutoff 5:00 PM EDT · Mon–Fri · next cutoff in 19h 35m
Arrives Tue, Oct 27 – Wed, Oct 28
Free shipping on orders over $200
Premium shipping insurance available
Add it at cart/checkout
Priority Overnight shipping available
Pick your speed at checkout

Chemical and Molecular Data

What is 9-Me-BC (9-Methyl-β-Carboline)?

9-Me-BC (9-methyl-β-carboline, also called 9-methylnorharmane, N-methylnorharmane, and 9-methyl-9H-pyrido[3,4-b]indole; CAS 2521-07-5) is a synthetic N-methylated β-carboline, a flat tricyclic aromatic heterocycle in which an indole ring is fused to a pyridine ring. It is a monoamine oxidase (MAO) inhibitor reference compound that inhibits MAO-A at lower concentrations than MAO-B. 9-Me-BC is not a peptide and not an amino acid, even though some searches call it a “9-Me-BC peptide.” Its activity in the published literature comes from the aromatic β-carboline ring system, with the methyl group on the indole nitrogen (N9) and the pyridine nitrogen (N2) left free.

In a luminescent MAO-Glo enzyme assay, 9-Me-BC inhibited MAO-A with an IC50 of 1 µM and MAO-B with an IC50 of 15.5 µM (Keller et al., 2020, PMC8592951). In a separate mitochondrial assay, 9-methylnorharman inhibited MAO-B-mediated oxidation of the reference substrate MPTP with an IC50 of 7.3 µM (Herraiz and Guillén, 2011). That is what 9-Me-BC does at the enzyme level: it slows the flavoenzymes that catalyze the oxidative deamination of biogenic amines, including dopamine.

Batch-verified for high analytical purity at Modern Aminos, 9-Me-BC is supplied in one laboratory format:

  • 15 mg dry-fill capsules, 60 units per capsule bottle

Laboratories building dopaminergic-pathway and monoamine-enzyme assay panels often place 9-Me-BC next to other public reference listings such as Bromantane, L-THP, NSI-189 Phosphate, and PRL-8-53. For a closer look at whether 9-Me-BC is a peptide, see Is 9-Me-BC a Peptide? 9-Methyl-β-Carboline Explained.

Chemical and Molecular Data for 9-Me-BC (9-Methyl-β-Carboline)

Compound Name 9-Me-BC (9-Methyl-β-Carboline)
Research Category Monoamine oxidase (MAO-A / MAO-B) inhibitor; N9-methylated β-carboline (pyrido[3,4-b]indole) heterocycle; dopaminergic-pathway and β-carboline structure-activity reference compound
Quantity / Formats Offered 15 mg Dry-Fill Capsules (60 units per capsule bottle)
Synonyms / Alt Names 9-Methyl-β-carboline; 9-methyl-9H-pyrido[3,4-b]indole; 9-methylpyrido[3,4-b]indole; 9-Methylnorharmane; 9-methylnorharman; N-Methylnorharmane; 9-methyl-9H-β-carboline; 9-Me-BC; 9MeBC
CAS Number 2521-07-5
PubChem CID 164979
UNII GC837J2CCJ
EPA DSSTox Substance ID DTXSID50179871
Chemical Formula C12H10N2
Molecular Weight 182.22 g/mol
Exact Mass 182.08440 Da
Stereochemistry Achiral; no defined or undefined stereocenters (planar tricyclic aromatic ring system)
Computed Properties (PubChem) XLogP3 2.3; TPSA 17.8 Ų; hydrogen-bond donors 0; hydrogen-bond acceptors 1; rotatable bonds 0
IUPAC Name 9-methylpyrido[3,4-b]indole
InChI InChI=1S/C12H10N2/c1-14-11-5-3-2-4-9(11)10-6-7-13-8-12(10)14/h2-8H,1H3
InChIKey MABOIYXDALNSES-UHFFFAOYSA-N
SMILES Code CN1C2=CC=CC=C2C3=C1C=NC=C3

Identity fields are drawn from PubChem CID 164979; quantity values come from the certificate in the Certificate of Analysis tab.

What are the Mechanisms of Action?

The biochemical targets and pathway logic of 9-Me-BC in laboratory research include:

  • Monoamine oxidase A and B inhibition: In a luminescent MAO-Glo assay with MAO-A and MAO-B enzymes, using clorgyline and pargyline as reference inhibitors, 9-Me-BC gave IC50 values of 1 µM for MAO-A and 15.5 µM for MAO-B, a 15.5-fold lower IC50 for MAO-A (Keller et al., 2020).
  • MAO-B substrate oxidation: In mitochondrial preparations, where MPTP oxidation was carried out by MAO-B, 9-methylnorharman inhibited the oxidation of MPTP to its pyridinium species (MPDP⁺/MPP⁺) with an IC50 of 7.3 µM, alongside norharman at 9.9 µM (Herraiz and Guillén, 2011).
  • Aromatic β-carboline scaffold: Fully aromatic β-carbolines such as norharman and harman inhibit recombinant MAO enzymes and are not themselves modified by MAO in HPLC kinetic assays (Herraiz and Chaparro, 2006). Norharman is a competitive, reversible inhibitor of MAO-A (Ki 1.2 µM) and MAO-B (Ki 1.12 µM) (Herraiz and Chaparro, 2005); 9-Me-BC is the N9-methyl derivative of that parent ring.
  • Tyrosine Hydroxylase and neurotrophic-factor gene expression: Gene-expression profiling links 9-Me-BC to increased expression of marker genes including Th, Dat and Aldh1a1 and of transcription factors including Nurr1 and Pitx3 (Hamann et al., 2008). Later work reports increased expression of neurotrophic-factor genes including Artn, Bdnf, Egln1, Tgfb2 and Ncam1, a dependence on phosphatidylinositol 3-kinase (PI3K) signaling, and a role for organic cation transporters (OCT) rather than the dopamine transporter (Keller et al., 2020).
  • N9 versus N2 methylation: The methyl group sits on the indole nitrogen (N9), leaving the pyridine nitrogen (N2) free. Purified phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28) catalyzed 2N-methylation of 9-methylnorharman at 21.1 pmol/h per unit PNMT, while it did not 9N-methylate the 2-methylnorharmanium cation (Gearhart et al., 2002).
  • Protonation and photochemistry: The pyridine nitrogen is the protonation site; ground- and excited-state pyridinic protonation of N9-methyl-β-carboline proceeds through hydrogen-bonded water adducts (Sánchez Coronilla et al., 2009). Photoexcited 9-methyl-β-carbolines act as UVA photosensitizers, and at neutral pH most DNA photodamage comes from the protonated excited form in a type-I reaction (Vignoni et al., 2013).
Assay Parameter 9-Me-BC Norharmane (9H-β-carboline) Source
IC50, MAO-A (MAO-Glo luminescent assay) 1 µM not reported in this source Keller 2020, Fig. 3c
IC50, MAO-B (MAO-Glo luminescent assay) 15.5 µM not reported in this source Keller 2020, Fig. 3d
IC50, MAO-B-mediated MPTP oxidation (mitochondrial preparation) 7.3 µM 9.9 µM Herraiz 2011, abstract
Ki, MAO-A (competitive, reversible) not reported 1.2 ± 0.18 µM Herraiz 2005, abstract
Ki, MAO-B (competitive, reversible) not reported 1.12 ± 0.19 µM Herraiz 2005, abstract
PNMT-catalyzed 2N-methylation rate 21.1 pmol/h per unit PNMT not reported in this source Gearhart 2002, abstract

What Does Published Research Show for 9-Me-BC?

Peer-reviewed literature on 9-Me-BC (9-Methyl-β-Carboline) and its parent ring norharmane centers on enzyme inhibition, gene-expression profiling, enzymatic N-methylation, and photophysics:

  • MAO-A and MAO-B inhibition (PMC): An open-access 2020 study reports IC50 values of 1 µM (MAO-A) and 15.5 µM (MAO-B) for 9-Me-BC in a MAO-Glo luminescent assay and links its gene-expression effects to PI3K signaling (PMC8592951).
  • MAO-B substrate oxidation (PubMed): 9-Methylnorharman (9-methyl-β-carboline) inhibited MAO-B-mediated oxidation of MPTP to its pyridinium species with an IC50 of 7.3 µM (PubMed 21554916).
  • β-Carboline MAO kinetics (PubMed): HPLC kinetic work with recombinant MAO shows that fully aromatic β-carbolines inhibit MAO without being oxidized by it (PubMed 16386263), and norharman is a competitive, reversible MAO-A and MAO-B inhibitor in the low-micromolar Ki range (PubMed 15582589).
  • Gene-expression profiling (PubMed): The first 9-Me-BC expression study reports increased transcripts for Shh, Wnt1, Wnt5a, En1, En2, Nurr1 and Pitx3 and for the marker genes Th, Dat and Aldh1a1 (PubMed 17913302).
  • Enzymatic N-methylation (PubMed): Purified PNMT methylates 9-methylnorharman at the pyridine nitrogen, a β-carboline 2N-methyltransferase activity inhibited by a selective PNMT inhibitor with an IC50 of 1.9 µM (PubMed 11900856).
  • Photophysics (PubMed): Acid dissociation constants, absorption and fluorescence spectra, fluorescence quantum yields and lifetimes, and singlet-oxygen quantum yields have been measured for 9-methyl-β-carbolines in aqueous solution from pH 4.0 to 14.5 (PubMed 28741707).
  • Chemical Directory & Structure Verification (PubChem): PubChem CID 164979 lists CAS 2521-07-5, formula C12H10N2, MW 182.22, exact mass 182.08440 Da, InChIKey MABOIYXDALNSES-UHFFFAOYSA-N, UNII GC837J2CCJ, and DSSTox DTXSID50179871 (PubChem 164979).
  • Analytical Quality: Why chromatographic testing matters for reference materials is covered in Modern Aminos’ note on HPLC testing.

How does 9-Me-BC compare to other compounds?

To map monoamine-enzyme and dopaminergic-pathway chemistry, researchers compare 9-Me-BC against its parent β-carboline, its methyl isomer, and other dopamine-pathway reference compounds, including several available at Modern Aminos:

Compound / Reference Primary Target Class Core Mechanism of Action Research Focus & Profile
9-Me-BC (9-Methyl-β-Carboline) N9-methyl β-carboline; MAO-A / MAO-B inhibitor Inhibits MAO-A (IC50 1 µM) ahead of MAO-B (IC50 15.5 µM); pyridine N2 free for protonation and enzymatic methylation Monoamine-enzyme and β-carboline structure-activity reference; CAS 2521-07-5
Norharmane (9H-β-carboline) Unsubstituted β-carboline; MAO-A / MAO-B inhibitor Competitive, reversible MAO inhibition (Ki 1.2 µM MAO-A, 1.12 µM MAO-B) Parent ring with an indole N-H; PubChem CID 64961
Harmane (1-methyl-β-carboline) C1-methyl β-carboline; MAO-A inhibitor Competitive MAO-A inhibition (Ki 55.54 nM) Same formula and molecular weight as 9-Me-BC (C12H10N2); PubChem CID 5281404
Bromantane Adamantane secondary amine / actoprotector class Reported TH transcriptional upregulation; GABA-transporter expression modulation Catecholamine-biosynthesis pathway chemistry; CAS 87913-26-6
L-THP Tetrahydroprotoberberine alkaloid / dopamine receptor antagonist Occupies dopamine D1, D2 and D3 receptors without activating them Receptor-level dopaminergic pharmacology; see also What Is L-THP?

Frequently Asked Questions (FAQs)

1. Is Modern Aminos a reliable place to buy 9-Me-BC (9-Methyl-β-Carboline)?

Modern Aminos publishes a third-party certificate from Vanguard Laboratory, an A2LA-accredited lab (certificate #6377.01.01), for 9-Me-BC. The 15 mg/unit capsule report (Lab ID V260513-21 001, reported 5/27/2026) lists HPLC-UV/VIS per-unit quantity results for three sampled capsules. If you want to buy 9-methyl-β-carboline as a documented reference material, the certificate is in the Certificate of Analysis tab.

2. Is 9-Me-BC a peptide or an amino acid?

Neither. 9-Me-BC is a small, flat tricyclic heterocycle, 9-methylpyrido[3,4-b]indole (C12H10N2, 182.22 g/mol, PubChem CID 164979). It has no amino-acid residues and no peptide bonds. Its indole half is the same ring system found in L-Tryptophan, which is one reason β-carbolines are sometimes grouped with amino-acid-derived compounds in search results. The full explanation is in Is 9-Me-BC a Peptide? 9-Methyl-β-Carboline Explained.

3. Is 9-Me-BC a nootropic, a supplement, or a research chemical?

9-Me-BC from Modern Aminos is a laboratory research compound with a third-party certificate, not a dietary supplement. Chemically it is an N-methylated β-carboline, and it is classified by its monoamine oxidase pharmacology and its β-carboline chemistry rather than by any nootropic label.

4. What is the molecular target and primary function of 9-Me-BC (9-Methyl-β-Carboline)?

The best-characterized molecular targets are the two monoamine oxidase isoforms. In a luminescent MAO-Glo assay, 9-Me-BC inhibited MAO-A with an IC50 of 1 µM and MAO-B with an IC50 of 15.5 µM (Keller et al., 2020). MAO enzymes are flavin adenine dinucleotide (FAD) flavoenzymes on the outer mitochondrial membrane that catalyze the oxidative deamination of biogenic and xenobiotic amines (Herraiz and Chaparro, 2006).

5. How does MAO inhibition by 9-Me-BC change amine oxidation in enzyme assays?

When MAO is inhibited, less substrate amine is oxidized to its aldehyde and pyridinium-type products in a given time. For MAO-B, 9-methylnorharman inhibited the oxidation of the reference substrate MPTP to its pyridinium species in mitochondrial preparations with an IC50 of 7.3 µM, close to norharman at 9.9 µM (Herraiz and Guillén, 2011). The lower IC50 for MAO-A (1 µM versus 15.5 µM) means MAO-A activity is reduced at lower concentrations in the same assay format (Keller et al., 2020).

6. What role does the N9 methyl group play?

The methyl group replaces the indole N-H hydrogen of norharmane. PubChem computes 0 hydrogen-bond donors and a TPSA of 17.8 Ų for 9-Me-BC, compared with 1 donor and 28.7 Ų for norharmane (PubChem CID 64961). The pyridine nitrogen (N2) stays free: it is the protonation site in solution (Sánchez Coronilla et al., 2009) and the site that phenylethanolamine N-methyltransferase methylates to give a 2,9-dimethyl-β-carbolinium cation (Gearhart et al., 2002).

7. How is 9-Me-BC different from norharmane and harmane?

Norharmane (9H-β-carboline, C11H8N2, 168.19 g/mol) is the unsubstituted parent ring. Harmane (1-methyl-β-carboline) carries its methyl group on carbon 1 instead of nitrogen 9, so it has exactly the same formula and molecular weight as 9-Me-BC (C12H10N2, 182.22 g/mol) but a different structure (PubChem CID 5281404). The InChIKey, MABOIYXDALNSES-UHFFFAOYSA-N for 9-Me-BC, is the quickest way to tell the two isomers apart.

8. What other names and identifiers does 9-Me-BC go by?

PubChem CID 164979 lists 9-Me-BC as 9-methyl-β-carboline, 9-methyl-9H-pyrido[3,4-b]indole, 9-methylnorharmane, N-methylnorharmane, and 9-methyl-9H-β-carboline, with CAS 2521-07-5, UNII GC837J2CCJ, and DSSTox DTXSID50179871. In older photophysics papers it is abbreviated MBC, and in URLs and catalogs the Greek β is often written out as “beta.”

9. What available formats does Modern Aminos offer for 9-Me-BC research?

Modern Aminos supplies 9-Me-BC in one format: 15 mg dry-fill capsules, 60 units per capsule bottle. A loose powder or liquid format is not offered for this listing.

10. How does 9-Me-BC compare to Bromantane and L-THP in dopamine-pathway assays?

The three act at different points in dopamine chemistry. L-THP is a receptor-level tool that occupies dopamine receptors without activating them, Bromantane is linked to transcriptional upregulation of Tyrosine Hydroxylase (TH), and 9-Me-BC acts on the MAO enzymes that oxidize monoamines, with additional literature on TH gene expression. See What Is L-THP? Levo-Tetrahydropalmatine Explained and Is Bromantane a Peptide? N-(4-bromophenyl)adamantan-2-amine Explained for those two compounds.

11. How does Modern Aminos verify the chemical identity and purity of 9-Me-BC?

Every batch of 9-Me-BC undergoes strict third-party analytical testing (including HPLC and Mass Spectrometry) to verify minimum 98%+ purity, correct molecular weight (182.22 g/mol), and complete absence of unreacted synthetic impurities or heavy metals. The current Vanguard Laboratory certificate (A2LA #6377.01.01) published in the Certificate of Analysis tab is an HPLC-UV/VIS per-unit quantity report for the 15 mg capsules. The identity fields on this page (CAS, InChI, InChIKey, SMILES) come from PubChem CID 164979.

12. What are the proper storage protocols for 9-Me-BC capsules?

Keep the capsule bottle sealed, cool, dry, and away from light. Follow the label on each lot. No storage temperature is printed on the current Vanguard certificate, so none is given here.

DISCLAIMER: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research use only. They are not approved for human consumption by the Food and Drug Administration (FDA). No products are approved for oral, sublingual, nor in vivo use. These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.

Capsule products are not intended for time-release and are for transport only.

DISCLAIMER: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research use only. They are not approved for human consumption by the Food and Drug Administration (FDA). No products are approved for oral, sublingual, nor in vivo use. These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.

0